GOLD KIDNEY HEALTH PLAN

Formulary Change Notice

Gold Kidney Health Plan may remove drugs from our formulary (list of covered drugs) or add rules about whether and when certain drugs are covered during the year. The chart below contains upcoming changes to the Gold Kidney Health Plan formulary. You may not be taking these drugs now. We provide you with these updates so that you know about future changes to our drug list. Please see Section 4 of your Monthly Prescription Drug Summary (Member Explanation of Benefits) for specific changes to drugs that you are currently taking.

CMS Formulary ID	Effective Date	Drug Name	Change Description	Reason Description	Alternate Drug and Tier
25216 25318	3/1/2025	SPRYCEL 20 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	DASATINIB 20 MG ORAL TABLET-5
25216 25318	3/1/2025	SPRYCEL 50 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	DASATINIB 50 MG ORAL TABLET-5
25216 25318	3/1/2025	SPRYCEL 70 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	DASATINIB 70 MG ORAL TABLET-5
25216 25318	3/1/2025	SPRYCEL 80 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	DASATINIB 80 MG ORAL TABLET-5

Last Updated: 10/24/2025

CMS Formulary ID	Effective Date	Drug Name	Change Description	Reason Description	Alternate Drug and Tier
25216 25318	3/1/2025	SPRYCEL 100 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	DASATINIB 100 MG ORAL TABLET-5
25216 25318	3/1/2025	SPRYCEL 140 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	DASATINIB 140 MG ORAL TABLET-5
25216 25318	3/1/2025	TAZORAC 0.05 % TOPICAL CREAM (G)	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	TAZAROTENE 0.05 % TOPICAL CREAM (G)-2
25216 25318	4/1/2025	MESNEX 400 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	MESNA 400 MG ORAL TABLET-5
25216 25318	4/1/2025	TRUSELTIQ 50 MG/DAY ORAL CAPSULE	DELETION OF DRUG FROM FORMULARY	NO LONGER FDA APPROVED	
25216 25318	4/1/2025	TRUSELTIQ 75 MG/DAY ORAL CAPSULE	DELETION OF DRUG FROM FORMULARY	NO LONGER FDA APPROVED	
25216 25318	4/1/2025	TRUSELTIQ 100 MG/DAY ORAL CAPSULE	DELETION OF DRUG FROM FORMULARY	NO LONGER FDA APPROVED	
25216 25318	4/1/2025	TRUSELTIQ 125 MG/DAY ORAL CAPSULE	DELETION OF DRUG FROM FORMULARY	NO LONGER FDA APPROVED	

CMS Formulary ID	Effective Date	Drug Name	Change Description	Reason Description	Alternate Drug and Tier
25216 25318	5/1/2025	NAMZARIC 14MG-10MG ORAL CAP SPR 24	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	MEMANTINE HCL-DONEPEZIL HCL ER 14MG-10MG ORAL CAP SPR 24-2
25216 25318	5/1/2025	NAMZARIC 21 MG-10MG ORAL CAP SPR 24	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	MEMANTINE HCL-DONEPEZIL HCL ER 21 MG-10MG ORAL CAP SPR 24-2
25216 25318	5/1/2025	NAMZARIC 28 MG-10MG ORAL CAP SPR 24	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	MEMANTINE HCL-DONEPEZIL HCL ER 14MG-10MG ORAL CAP SPR 24-2
25216 25318	6/1/2025	PURIXAN 20 MG/ML ORAL SUSP	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	MERCAPTOPURINE 20 MG/ML ORAL ORAL SUSP-5
25216 25318	8/1/2025	APTIOM 200 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	ESLICARBAZEPINE ACETATE 200 MG ORAL TABLET-5
25216 25318	8/1/2025	APTIOM 400 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	ESLICARBAZEPINE ACETATE 400 MG ORAL TABLET-5
25216 25318	8/1/2025	APTIOM 600 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	ESLICARBAZEPINE ACETATE 600 MG ORAL TABLET-5
25216 25318	8/1/2025	APTIOM 800 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	ESLICARBAZEPINE ACETATE 800 MG ORAL TABLET-5

CMS Formulary ID	Effective Date	Drug Name	Change Description	Reason Description	Alternate Drug and Tier
25216 25318	8/1/2025	JYNARQUE 15 MG-15MG ORAL TABLET SEQ	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	TOLVAPTAN 15 MG-15MG ORAL TABLET SEQ-5
25216 25318	8/1/2025	JYNARQUE 30 MG-15MG ORAL TABLET SEQ	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	TOLVAPTAN 30 MG-15MG ORAL TABLET SEQ-5
25216 25318	8/1/2025	JYNARQUE 45 MG-15MG ORAL TABLET SEQ	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	TOLVAPTAN 45 MG-15MG ORAL TABLET SEQ-5
25216 25318	8/1/2025	JYNARQUE 60 MG-30MG ORAL TABLET SEQ	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	TOLVAPTAN 60 MG-30MG ORAL TABLET SEQ-5
25216 25318	8/1/2025	JYNARQUE 90 MG-30MG ORAL TABLET SEQ	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	TOLVAPTAN 90 MG-30MG ORAL TABLET SEQ-5
25216 25318	9/1/2025	COMPLERA 200-25-300 ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	EMTRICITABINE-RILPIVIRNE-TENOF 200-25-300 ORAL TABLET-5
25216 25318	9/1/2025	PROMACTA 12.5 MG ORAL POWD PACK	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	ELTROMBOPAG OLAMINE 12.5 MG ORAL POWD PACK-5
25216 25318	9/1/2025	PROMACTA 25 MG ORAL POWD PACK	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	ELTROMBOPAG OLAMINE 25 MG ORAL POWD PACK-5

CMS Formulary ID	Effective Date	Drug Name	Change Description	Reason Description	Alternate Drug and Tier
25216 25318	9/1/2025	PROMACTA 12.5 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	ELTROMBOPAG OLAMINE 12.5 MG ORAL TABLET-5
25216 25318	9/1/2025	PROMACTA 25 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	ELTROMBOPAG OLAMINE 25 MG ORAL TABLET-5
25216 25318	9/1/2025	PROMACTA 50 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	ELTROMBOPAG OLAMINE 50 MG ORAL TABLET-5
25216 25318	9/1/2025	PROMACTA 75 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	ELTROMBOPAG OLAMINE 75 MG ORAL TABLET-5
25216 25318	8/30/2025	IXCHIQ 1000 TCID INTRAMUSC. VIAL	REMOVAL DUE TO FDA MANDATED MARKET WITHDRAWAL	REMOVAL DUE TO FDA MANDATED MARKET WITHDRAWAL	
25216 25318	10/1/2025	ENTRESTO 24 MG-26MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	SACUBITRIL-VALSARTAN 24 MG-26MG ORAL TABLET-2
25216 25318	10/1/2025	ENTRESTO 97MG-103MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	SACUBITRIL-VALSARTAN 97MG-103MG ORAL TABLET-2
25216 25318	10/1/2025	ENTRESTO 49 MG-51MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	SACUBITRIL-VALSARTAN 49 MG-51MG ORAL TABLET-2
25216 25318	10/1/2025	JYNARQUE 15 MG ORAL TABLET		REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE	TOLVAPTAN 15 MG ORAL TABLET-5

CMS Formulary ID	Effective Date	Drug Name	Change Description	Reason Description	Alternate Drug and Tier
			BRAND DELETION, ADD GENERIC	TO ADDITION OF NEW GENERIC EQUIVALENT	
25216 25318	10/1/2025	JYNARQUE 30 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	TOLVAPTAN 30 MG ORAL TABLET-5
25216 25318	10/1/2025	FYCOMPA 2 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PERAMPANEL 2 MG ORAL TABLET-2
25216 25318	10/1/2025	FYCOMPA 4 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PERAMPANEL 4 MG ORAL TABLET-5
25216 25318	10/1/2025	FYCOMPA 6 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PERAMPANEL 6 MG ORAL TABLET-5
25216 25318	10/1/2025	FYCOMPA 8 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PERAMPANEL 8 MG ORAL TABLET-5
25216 25318	10/1/2025	FYCOMPA 10 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PERAMPANEL 10 MG ORAL TABLET-5
25216 25318	10/1/2025	FYCOMPA 12 MG ORAL TABLET	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PERAMPANEL 12 MG ORAL TABLET-5
25216 25318	11/1/2025	EPRONTIA 25 MG/ML ORAL SOLUTION	BRAND DELETION, ADD GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE	TOPIRAMATE 25 MG/ML ORAL SOLUTION-2

CMS Formulary ID	Effective Date	Drug Name	Change Description	Reason Description	Alternate Drug and Tier
				TO ADDITION OF NEW GENERIC EQUIVALENT	
25216 25318	11/14/2025	OCALIVA 5 MG ORAL TABLET	DELETION OF DRUG FROM FORMULARY	PRODUCT WITHDRAWN FROM MARKET	
25216 25318	11/14/2025	OCALIVA 10 MG ORAL TABLET	DELETION OF DRUG FROM FORMULARY	PRODUCT WITHDRAWN FROM MARKET	